SABS vs SEPN

SAB Biotherapeutics, Inc. vs Septerna, Inc. — Valuation Comparison 2026

By CirclFi Research Team · Updated 2026-06-03 · Data from SEC EDGAR, FRED & GDELT

Quick Summary — SEPN scores higher on quality with 6.9/10 vs SABS's 5.0/10. SABS trades at $3.48 while SEPN trades at $29.94. Both analyzed daily using SEC EDGAR data across 13 institutional models.

SABS

Biotechnology
SAB Biotherapeutics, Inc.
Quality
5.0
out of 10
Value Trap
41
WARN
Price
$3.48
Last close
Models
12/13
Active
VS

SEPN

Biotechnology
Septerna, Inc.
Quality
6.9
out of 10
Value Trap
12
SAFE
Price
$29.94
Last close
Models
10/13
Active
SABS
Earnings Power Value sees +77.9% upside
Value Trap 41/100 — caution
SEPN
2 models active
Limited to 2/13 visible models

SABS vs SEPN — Fair Value Comparison

SABS
$0$2$5$7 Price$3.48 Bayesian …$1.25 (-64.1%) Earnings …$6.17 (+77.9%)
SEPN
$0$12$24$35 Price$29.94 Bayesian …$15.33 (-48.8%) Dynamic N…$4.39 (-85.3%)
Market Price Model 1 Model 2

Model-by-Model Comparison

ModelType SABS Fair ValueSABS Upside SEPN Fair ValueSEPN Upside
Bayesian DCF Intrinsic $1.25 -64.1% $15.33 -48.8%
Earnings Power Value Intrinsic $6.17 +77.9% — —
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.90 -45.4% $4.39 -85.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%

SABS vs SEPN — Which Stock Is More Undervalued in 2026?

SEPN scores higher with a 6.9/10 quality rating vs SABS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do SABS and SEPN Valuations Compare?

At $3.48, SABS trades +64.1% above its Bayesian DCF fair value of $1.25, while SEPN at $29.94 trades +48.8% above its estimate of $15.33. SABS shows a wider gap between price and intrinsic value.

Quality of Company: SABS vs SEPN

SABS earns a Quality of Company score of 5.0/10 compared to SEPN's 6.9/10. This moderate difference suggests one company has an edge in fundamental quality, though both may offer investment merit depending on valuation. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: SABS vs SEPN

SABS carries a WARN value trap risk (41/100) while SEPN shows SAFE risk (12/100). Stocks with value trap scores above 40 may appear undervalued but face deteriorating fundamentals — declining margins, rising debt, or shrinking revenue can make the apparent discount a trap.

Both in Biotechnology

Both SABS and SEPN operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare SABS vs SEPN differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo  ·  FactSet: ~$1,000/mo  ·  CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

SABS
View Full SAB Biotherapeutics, Inc. Analysis →
SEPN
View Full Septerna, Inc. Analysis →
See all Biotechnology stocks →